Fresenius Kabi Oncology Peer Comparison

NSE: FKONCO | BSE: 532545

₹132.50

₹0.45 (0.34%)

As on 02-Jan-2014IST

Market cap

₹2,255 Cr

Revenue (TTM)

₹813 Cr

P/E Ratio

--

P/B Ratio

3.6

Div. Yield

0 %

Edit

	Fresenius Kabi Oncology	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Market cap (₹ Cr)	2,255	32,864	33,015	31,746	29,317
Revenue (₹ Cr)	813	9,779	3,751	1,593	2,100
Net Profit (₹ Cr)	75.13	-270.51	405.00	438.64	324.79
Net Margin (%)	8.86	-2.71	10.48	27.16	15.36
RoE (%)	5.47	-2.55	7.91	25.02	24.02
Price to Earnings	--	--	80.52	72.29	90.25
Price-To-Book	3.60	4.03	6.40	17.09	20.70

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Fresenius Kabi Oncology	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Operating Revenue	813.05	9,151.18	3,012.00	1,006.88	1,284.27
Total Income	848.26	9,312.95	3,074.00	1,023.80	1,296.22
Total Expenditure	685.51	7,733.31	2,619.00	774.80	1,028.33
EBITDA	127.55	1,417.87	393.00	232.07	255.95
Depreciation	52.05	816.34	217.00	26.62	36.59
EBIT	75.50	601.53	176.00	205.45	219.36
Interest	9.51	421.59	254.00	6.22	36.78
Other Income	35.20	161.77	62.00	16.93	11.95
Exceptional Items	--	--	--	--	--
Profit before Tax	101.19	414.64	-16.00	216.16	194.52
Provision for Tax	26.06	323.51	41.00	55.75	60.16
Profit after Tax	75.13	91.13	-57.00	160.42	134.36

Liabilities (₹ Cr)

	Fresenius Kabi Oncology	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Shareholder's Funds	1,411.36	8,125.47	4,353.00	1,309.63	540.98
Minority Interest	--	--	304.00	10.45	0.00
Non-Current Liabilities	156.12	3,392.72	887.00	26.93	122.65
Current Liabilities	307.18	3,850.56	2,042.00	202.25	786.03
Total Liabilities	1,874.66	15,513.53	8,100.00	1,549.26	1,451.43

Assets (₹ Cr)

	Fresenius Kabi Oncology	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Non-Current Assets	694.42	9,487.47	5,017.00	757.63	386.29
Current Assets	1,180.24	5,881.28	2,465.00	791.64	1,063.37
Total Assets	1,874.66	15,513.53	8,100.00	1,549.26	1,451.43
Total Debt*	117.72	4,720.27	1,859.00	8.18	393.17
Net Current Assets	873.06	2,030.72	423.00	589.39	277.34
Contingent Liabilities	161.34	99.76	770.26	15.38	12.25

Cashflow (₹ Cr)

	Fresenius Kabi Oncology	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Cash From Operating Activities	-63.76	892.30	-22.00	118.34	159.18
Cash Flow from Investing Activities	-46.22	-477.46	-783.00	-223.94	-64.81
Cash from Financing Activities	-77.73	-440.83	409.00	261.12	-39.81
Net Cash Inflow / Outflow	-187.70	-25.99	-396.00	155.52	54.56

Ratios

Profitability Ratios

	Fresenius Kabi Oncology	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
ROCE (%)	7.33	6.61	4.07	20.14	26.97
ROE (%)	5.47	1.14	-1.48	16.19	30.68
ROA (%)	3.88	0.60	-0.78	12.13	10.50
EBIT Margin (%)	20.02	17.26	15.11	24.73	20.86
Net Margin (%)	8.86	0.98	-1.85	15.67	10.37
Cash Profit Margin (%)	15.64	8.54	4.14	18.58	7.13

Growth Ratios

	Fresenius Kabi Oncology	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Revenue Growth (%)	3.39	11.99	7.65	40.34	50.40
EBIT Growth (%)	17.94	15.16	272.95	83.12	54.77
Net Profit Growth (%)	38.61	411.39	87.92	229.35	47.63
EPS Growth (%)	38.61	410.84	90.35	67.16	45.69
Book Value Growth (%)	5.70	2.28	29.77	94.96	42.49

Valuation Ratios

	Fresenius Kabi Oncology	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Price / Earnings	0.00	326.26	0.00	62.97	0.00
Price / Book Value	0.00	3.69	5.31	15.26	0.00
Dividend Yield (%)	--	0.06	0.00	0.06	--
EV/EBITDA	0.99	21.49	54.36	79.31	1.09
Market Cap (₹ Cr)	0.00	29,731.27	23,064.69	19,988.69	0.00

Solvency Ratios

	Fresenius Kabi Oncology	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Debt to Equity	0.08	0.59	0.43	0.01	0.76
Short term debt to equity ratio	0.06	0.12	0.11	0.01	0.54
Current Ratio	3.84	1.53	1.21	3.91	1.35
Quick Ratio	1.98	0.93	0.85	3.02	0.69
Interest Coverage	11.64	1.98	0.94	35.76	6.29

Operating Efficiency Ratios

	Fresenius Kabi Oncology	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Debtors to sales (%)	46.76	25.67	21.95	28.85	25.21
Asset Turnover	0.42	0.70	0.53	0.76	1.87
Receivable days	163.95	77.05	60.36	90.06	47.59
Inventory Days	262.96	77.13	64.42	61.02	62.58
Payable days	179.42	173.49	218.94	96.06	228.78
Cash Conversion Cycle	247.48	-19.30	-94.15	55.02	-118.62